IAVI’s Post

Watch now! IAVI's Dr. Gaudensia Mutua and HJF Medical Research International's Dr. Abdulwasiu Bolaji Tiamiyu were recently interviewed by NTAi News about IAVI C105, the first #LassaFever vaccine candidate to enter a Phase 2 clinical trial. They discussed African scientists' and communities' leading roles in developing this vaccine – plus, how these efforts drive forward global health progress. ▶ https://lnkd.in/ey23GxM3 CEPI (Coalition for Epidemic Preparedness Innovations)

Saturday, July 6, is World Zoonoses Day! On this date in 1885, the first rabies vaccine was administered. This year, IAVI is marking progress toward a vaccine for a globally important zoonotic illness: Lassa fever. A new website feature highlights some recent publications and announcements marking some exciting steps forward: 🔵 An updated Lassa research roadmap in The Lancet co-authored by Swati Gupta, IAVI’s head of emerging infectious diseases. 🔵 The announcement of the start of vaccinations in a Phase 2 clinical trial of IAVI’s Lassa fever vaccine candidate in Liberia. 🔵 A commentary on African leadership in Lassa vaccine development by Dr. Gaudensia Mutua, a medical monitor on our Lassa trials. Read and share the feature to help IAVI and our partners celebrate these developments!👇 #globalhealth #lassafever #vaccineswork #partnerships #outsmartepidemics CEPI (Coalition for Epidemic Preparedness Innovations) | Global Health EDCTP3 | National Institute of Allergy and Infectious Diseases (NIAID) | Viral Hemorrhagic Fever Consortium | Batavia Biosciences

📢 “Many EIDs are being underestimated,” stated Swati Gupta, Ph.D., in a recent interview with Global Health Hub Netherlands. As IAVI’s Vice President and Head of Emerging Infectious Diseases, Gupta is attuned to the public health challenges posed by the global spread of #EIDs — including Lassa fever, Marburg virus, and Sudan Ebolavirus. According to Gupta, these diseases cannot be tackled without addressing broader pandemic preparedness initiatives and healthcare equity concerns. The interview further highlights IAVI’s efforts to promote local capacity strengthening and develop globally accessible vaccines, with the support of the Dutch Ministry of Foreign Affairs and the Dutch Global Health Hub. Read the full article to learn more: https://ow.ly/vrjC50SqtWS

#HIVprevention initiatives must represent and center LGBTQIA communities, researchers, advocates, and policymakers—this #Pride and always. 🌈 Through the ADVANCE partnership (USAID), IAVI supports key research and policy efforts impacting LGBTQIA communities across sub-Saharan Africa. Check out and amplify these resources. ⬇️ - National Guidance on Integrating Mental Health (2022): https://ow.ly/683350SprPB - Key Population Size Estimation (KPSE) in Kenya (2022): https://ow.ly/CfnJ50SprPF - JIAS Supplement: Engagement of African men and transgender women who have sex with men in HIV research (2020): https://ow.ly/MgzG50SprPz - National Implementation Guidelines for HIV and STI Programming Among Young Key Populations (2018): https://ow.ly/eQqY50Sps4n - National Violence Prevention and Response Protocol - Kenya (2017): https://ow.ly/Nx5V50Sps7Z - Respect, Protect, Fulfill: MSM Research Guidance (2015): https://ow.ly/r5hy50SprPE

IAVI congratulates our partner PREVAIL in Liberia on starting vaccinations in a Phase 2a clinical trial of IAVI’s Lassa fever vaccine candidate! PREVAIL expects to enroll 204 participants at the JFK Hospital in Monrovia, Montserrado County. This Phase 2a study is the next step of IAVI and CEPI (Coalition for Epidemic Preparedness Innovations)'s Lassa vaccine development partnership, launched in 2018. Importantly, it’s the most advanced clinical trial of a Lassa vaccine to date. Vaccinations are ongoing in Nigeria, and we expect to enroll additional participants in Ghana. Lassa fever is one of the pathogens in the World Health Organization R&D Blueprint list of epidemic threats needing urgent R&D action. No vaccine is available for this viral hemorrhagic illness, and treatment is limited, despite seasonal outbreaks and high case fatality rates. Read more: https://lnkd.in/dFwNeHrf

IAVI and partners in the EDCTP-funded UPTAKE study are proud to share a the first publication from Kenneth R. Katumba. Kenneth is based at MRC/UVRI & LSHTM Uganda Research Unit and one of two UPTAKE PhD candidates enrolled at London School of Hygiene and Tropical Medicine, U. of London. The paper, 'Understanding the contexts in which female sex workers sell sex in Kampala, Uganda: a qualitative study' discusses the value of researchers and implementers in considering the differences in the contexts, challenges, and risks of where women sell sex to design innovative interventions and programs that reach and include all women. 📰 Read it at: https://lnkd.in/e6irR3pE Busara | KAVI Institute of Clinical Research (KAVI-ICR) | Global Health EDCTP3